Drugs / ALLOB®
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02205138 | Oct 2014 → Feb 2019 | intervertebral disk degenerative disorder | Bone Therapeutics S.A | Completed | No outcome recorded |
| Phase 2 | NCT02328287 | Sep 2014 → Apr 2018 | — | Bone Therapeutics S.A | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLOB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02205138 ↗ |
| Modality | Cell therapy | “a proprietary population of allogeneic osteoblastic cells” NCT02205138 ↗ |
| Route | Other | “Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia” NCT02205138 ↗ |